Verve Therapeutics Income Statement

Financials in millions USD. Fiscal year is February - January.

Millions USD. Fiscal year is Feb - Jan.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '25 Apr 30, 2025	Jan '25 Jan 31, 2025	Jan '24 Jan 31, 2024	Jan '23 Jan 31, 2023	Jan '22 Jan 31, 2022
Revenue	904.42	861.61	699.57	552.83	450.04
Revenue Growth (YoY)	63.60%	23.16%	26.54%	22.84%	-
Cost of Revenue	336.05	305.73	276.48	199.36	114.7
Gross Profit	568.38	555.88	423.09	353.47	335.33
Selling, General & Admin	678.47	574.88	574.89	431.89	275.35
Research & Development	195.08	169.73	180.78	159.48	119.53
Operating Expenses	873.88	744.61	755.67	591.37	394.88
Operating Income	-305.51	-188.73	-332.58	-237.9	-59.55
Interest Expense	-162.8	-186.65	-187.06	-76.34	-2.68
Interest & Investment Income	5.41	4.16	10.66	2.29	0.73
Other Non Operating Income (Expenses)	-4.4	-5.4	-3.22	-3.15	-0.82
EBT Excluding Unusual Items	-467.3	-376.63	-512.2	-315.1	-62.31
Merger & Restructuring Charges	-	-	-0.15	-78.26	-
Asset Writedown	-	-	-	-	-0.74
Pretax Income	-467.3	-376.63	-512.35	-393.36	-63.06
Income Tax Expense	-53.34	-60.8	-116.98	-60.86	0.1
Net Income	-413.97	-315.83	-395.37	-332.5	-63.16
Preferred Dividends & Other Adjustments	736.97	764.55	583.67	101.4	-
Net Income to Common	-1,151	-1,080	-979.04	-433.9	-63.16
Shares Outstanding (Basic)	163	84	81	80	-
Shares Outstanding (Diluted)	163	84	81	80	-
Shares Change (YoY)	105.10%	3.68%	1.52%	-	-
EPS (Basic)	-7.06	-12.91	-12.12	-5.46	-
EPS (Diluted)	-7.06	-12.91	-12.12	-5.46	-
Free Cash Flow	-154.78	-111.75	-252.93	-327.82	-12.84
Free Cash Flow Per Share	-0.95	-1.33	-3.13	-4.12	-
Gross Margin	62.84%	64.52%	60.48%	63.94%	74.51%
Operating Margin	-33.78%	-21.91%	-47.54%	-43.03%	-13.23%
Profit Margin	-127.26%	-125.39%	-139.95%	-78.49%	-14.03%
Free Cash Flow Margin	-17.11%	-12.97%	-36.16%	-59.30%	-2.85%
EBITDA	-82.48	48.51	-68.94	-106.7	-36.76
EBITDA Margin	-9.12%	5.63%	-9.85%	-19.30%	-8.17%
D&A For EBITDA	223.03	237.25	263.64	131.2	22.79
EBIT	-305.51	-188.73	-332.58	-237.9	-59.55
EBIT Margin	-33.78%	-21.91%	-47.54%	-43.03%	-13.23%
Revenue as Reported	904.42	861.61	699.57	552.83	450.04
Advertising Expenses	-	25.5	22.3	20	-

Updated Jun 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q